Tanaxel (Paclitaxel)

 

Model: Liquid Injection (in vial)

Category: Pharmaceutical

Exhibitor: CKD OTTO PHARMACEUTICALS

Booth No: M625

 

Characteristic

 

Strength : 30 mg, 100 mg & 300 mg
Dosage form : Liquid Injection
Indication : Ovarian carcinoma, Breast carcinoma, NSCLC, etc.

Ovarian carcinoma
1. First-line therapy in combination with a platinum compound for the treatment of advanced metastatic carcinoma of the ovary.
2. Second-line therapy for the treatment of advanced metastatic carcinoma of the ovary.

Breast carcinoma
1. Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy.
2. Therapy after relapse within 6 months of adjuvant therapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Non-small cell lung carcinoma (NSCLC)
1. First-line therapy in combination with a platinum compound for the treatment of non-small cell carcinoma of the lung in patients who are not candidates for potentially curative surgery and / or radiation therapy.

 

Other Products

 

• 

  Irinobell (Irinotecan)

• 

  Kemobotin (Carboplatin)

• 

  Kemotrexate (Methotrexate)

• 

  Tezobell (Bortezomib)

• 

  Gemtan (Gemcitabine)

• 

  Vinobell (Vinorelbine)

• 

  Belloxa (Oxaliplatin)

• 

  Pemecine (Pemetrexed)

• 

  Belotaxel (Docetaxel)

 

 

 

Back